Updated analysis of overall survival in randomized phase III study of idelalisib in combination with bendamustine and rituximab in patients with relapsed/refractory CLL Meeting Abstract
| Authors: | Zelenetz, A. D.; Brown, J. R.; Delgado, J.; Eradat, H.; Ghia, P.; Jacob, A.; Jurczak, W.; Loscertales, J.; MacDonald, D.; Morschhauser, F.; De la Serna, J.; Shadman, M.; Pocock, C.; Adewoye, A. H.; Kim, Y.; Simpson, D.; Stilgenbauer, S. |
| Abstract Title: | Updated analysis of overall survival in randomized phase III study of idelalisib in combination with bendamustine and rituximab in patients with relapsed/refractory CLL |
| Meeting Title: | 58th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 128 |
| Issue: | 22 |
| Meeting Dates: | 2016 Dec 3-6 |
| Meeting Location: | San Diego, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2016-12-02 |
| Language: | English |
| ACCESSION: | WOS:000394446805073 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood.V128.22.231.231 |
| Notes: | Meeting Abstract: 231 -- Source: Wos |
